SCHEMBL31258190

SCHEMBL31258190

CC(C)(C)OC(=O)n1ncc(B2OC(C)(C)C(C)(C)O2)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.40
UCHL1 P09936 1/20 0.39
ELANE P08246 1/20 0.36
FFAR1 O14842 1/20 0.36
FAAH O00519 1/20 0.35
NR1H2 P55055 1/20 0.34
AAK1 Q2M2I8 2/20 0.33
DGAT1 O75907 1/20 0.33
LIPE Q05469 3/20 0.32
PRMT5 O14744 1/20 0.32
WDR77 Q9BQA1 1/20 0.32
ROCK2 O75116 1/20 0.31
CHEK2 O96017 1/20 0.31
PRKACA P17612 1/20 0.31
RPS6KA3 P51812 1/20 0.31
PAK1 Q13153 1/20 0.31
ROCK1 Q13464 1/20 0.31
DYRK1A Q13627 1/20 0.31
PRKD2 Q9BZL6 1/20 0.31
BACE1 P56817 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18689166 0.86 UCHL1 (0.39) USP30UCHL1ELANEFFAR1FAAH
SCHEMBL31258189 0.84 UCHL1 (0.40) USP30UCHL1ELANEFFAR1FAAH
SCHEMBL31710740 0.81 USP30 (0.39) USP30UCHL1ELANEFFAR1FAAH
SCHEMBL29821684 0.77 USP30 (0.38) USP30UCHL1ELANEFFAR1AAK1
SCHEMBL3709336 0.77 USP30 (0.38) USP30UCHL1ELANEFFAR1AAK1
SCHEMBL30293091 0.76 USP30 (0.39) USP30UCHL1ELANEFFAR1NR1H2
SCHEMBL22438298 0.76 USP30 (0.39) USP30UCHL1ELANEFFAR1NR1H2
SCHEMBL15412342 0.75 USP30 (0.40) USP30UCHL1ELANEFFAR1FAAH
SCHEMBL31258155 0.74 USP30 (0.40) USP30UCHL1FFAR1NR1H2AAK1
SCHEMBL21157350 0.73 UCHL1 (0.44) USP30UCHL1FFAR1NR1H2AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4698529-A1 BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2026-02-25 EP disclosed
US-20240360139-A1 BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. 2024-10-31 US disclosed
WO-2024220173-A1 BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF Genosco Inc. (US) 2024-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360139-A1 BLOOD BRAIN BARRIER PENETRATING SELECTIVE INHIBITORS OF ROCK2 PROTEIN KINASES AND USES THEREOF ROCK2, ROCK1, MYLK3 USP30 3342/4885UCHL1 3184/4885ELANE 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.